Albert Bourla, Pfizer CEO (John Thys, Pool via AP Images)

Covid-19 roundup: Pfiz­er/BioN­Tech sub­mit vac­cine da­ta to FDA for younger chil­dren; Doc­tors kept pre­scrib­ing hy­drox­y­chloro­quine

Pfiz­er and BioN­Tech said Tues­day they sub­mit­ted to FDA pos­i­tive da­ta from a Phase II/III tri­al of their Covid-19 vac­cine in chil­dren aged 5 to less than 12 years old.

A for­mal EUA sub­mis­sion for the vac­cine in these chil­dren is ex­pect­ed to fol­low “in the com­ing weeks,” the com­pa­nies said in a state­ment.

The tri­al of 2,268 healthy par­tic­i­pants aged 5 to less than 12 years old showed the vac­cine was safe and elicit­ed ro­bust neu­tral­iz­ing an­ti­body re­spons­es us­ing a two-dose reg­i­men of 10 μg dos­es, which is one-third the dose that’s ad­min­is­tered to adults.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.